EU and US could reach trade deal this weekend - Reuters
Kim Hyong, the Chief Medical (TASE:BLWV) Officer of Alignment Healthcare, Inc. (NASDAQ:ALHC), recently sold shares of the company’s common stock for a total value of $135,570. The transactions took place on March 19, 2025, and involved the sale of 8,266 shares. The shares were sold at a weighted-average price ranging from $16.088 to $16.9588 per share. The stock has shown remarkable momentum, delivering a 258.87% return over the past year and currently trades near its 52-week high of $17.27. According to InvestingPro, the company’s market capitalization stands at $3.3 billion.
According to the filing, the sales were made to cover tax withholding obligations related to the vesting of restricted stock units and were not discretionary trades by Hyong. Following these transactions, Hyong retains ownership of 536,101 shares of Alignment Healthcare. InvestingPro analysis reveals 11 additional key insights about ALHC’s performance and valuation, available in the comprehensive Pro Research Report, which provides deep-dive analysis of 1,400+ top US stocks.
In other recent news, Alignment Healthcare reported strong financial results for the fourth quarter of 2024, surpassing analysts’ expectations. The company achieved an earnings per share (EPS) of -0.16, beating the forecast of -0.18, and recorded revenue of $701.2 million, exceeding the anticipated $674.97 million. This performance highlights Alignment Healthcare’s ability to consistently exceed market predictions. Additionally, the company experienced a 59% increase in membership, contributing to a total revenue of $2.7 billion for the year, marking a 48% year-over-year growth.
Looking ahead, Alignment Healthcare has provided guidance for 2025, projecting revenue between $3.72 billion and $3.78 billion, indicating a 40% growth at the midpoint. The company also expects its adjusted gross profit to range from $415 million to $445 million. Piper Sandler and Raymond (NSE:RYMD) James have both expressed confidence in the company’s future, with Piper Sandler raising its price target to $21 and maintaining an Overweight rating, while Raymond James increased its target to $19 and reiterated a Strong Buy rating.
Both firms highlighted Alignment Healthcare’s strategic approach and operational scale as key factors in its promising outlook. The company has also projected health plan membership to grow to between 227,000 and 233,000 by the end of 2025, reflecting its expansion strategy and market positioning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.